Sign In
Buy CALA
$0.0002
+0 (+0%)
At Close: Jun 03, 2026
Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference
08:05pm, Tuesday, 06'th Sep 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan
Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference
04:05pm, Tuesday, 06'th Sep 2022
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan M
Why Bed Bath & Beyond Jumped Around 25%; Here Are 68 Biggest Movers From Yesterday
09:23am, Tuesday, 30'th Aug 2022 Benzinga
Gainers
American Virtual Cloud Technologies, Inc. (NASDAQ: AVCT) climbed 156.3% to close at $0.3750 on Monday. American Virtual Cloud Technologies shares gained around 8% on Friday after the company
This Small Cap Cancer Stock Gets An Upgrade And Price Target Bump On 'Clinical Programs Progress'
07:52pm, Monday, 29'th Aug 2022 Benzinga
HC Wainwright updated its model on Calithera Biosciences Inc (NASDAQ: CALA), reflecting the recent Q2 earnings with no revenues and a net loss of $1.69 per share for 2022.
The analyst upgraded
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022
02:11pm, Monday, 29'th Aug 2022 Benzinga
Upgrades
According to Argus Research, the prior rating for AstraZeneca PLC (NASDAQ:AZN) was changed from Hold to Buy. For the second quarter, AstraZeneca had an EPS of $0.86, compared to year-ago quar
Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday
06:55am, Monday, 29'th Aug 2022 Benzinga
Gainers
Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.
Minerva Neuroscien
Calithera Biosciences (CALA) Q2 2022 Earnings Call Transcript
03:00am, Tuesday, 16'th Aug 2022 The Motley Fool
CALA earnings call for the period ending June 30, 2022.
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q2 2022 Results - Earnings Call Transcript
08:42pm, Monday, 15'th Aug 2022
Calithera Biosciences, Inc. (NASDAQ:CALA ) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Stephanie Wong - Chief Financial Officer Susan Molineaux - Founder, Presiden
Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
08:05pm, Monday, 15'th Aug 2022 GlobeNewswire Inc.
-- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, August 15, 2022 -- -- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, August 15, 2022 --
What Is a Reverse Stock Split and How Does It Work?
12:42pm, Thursday, 28'th Jul 2022
We've seen a spate of stock splits in 2022, including from high-profile companies, such as Amazon (NASDAQ: AMZN ) and Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ). But while a stock split may too familiar
Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From Yesterday
08:40am, Thursday, 21'st Jul 2022 Benzinga
Gainers
Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednesday. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022.
Direct Digital Ho
Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences
08:01pm, Wednesday, 13'th Jul 2022 GlobeNewswire Inc.
-- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- -- First data from phase 1 investigator-sponsored
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer
08:01pm, Wednesday, 06'th Jul 2022 GlobeNewswire Inc.
-- Patients with tumors harboring NRF2-mutations have a poorer prognosis and no available targeted therapies -- SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences,
What is a Reverse Stock Split and How Does it Work?
08:15pm, Monday, 27'th Jun 2022
Reverse stock splits are not that common and often are associated with some trouble brewing at the company. Therefore, one must do a thorough study before deciding what to do what with the stock of a
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma
08:05pm, Thursday, 23'rd Jun 2022 GlobeNewswire Inc.
-- Novel biomarker will be used to identify patients in genetically defined subgroup associated with poorer outcomes
